drugset
drugset / Trial / NCT05319587

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT05319587 ↗

Phase 1/2 Completed 22 enrolled Moleculin Biotech, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabine for the treatment of subjects with AML.

Timeline

Start
2022-09-29
Primary completion
2023-08-02
Completion
2023-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject NAXTARUBICIN Small molecule 190 mg/m2 Intravenous
Subject NAXTARUBICIN Small molecule 210 mg/m2 Intravenous
Subject NAXTARUBICIN Small molecule 230 mg/m2 Intravenous
Background Cytarabine Small molecule 2 g Intravenous

Indications

acute myeloid leukemia